Within Major Pharmaceutical Preparations industry Protagenic Therapeutics Inc new booked the highest Quick Ratio than Protagenic Therapeutics Inc New in the first quarter 2026. While total ranking remained the same in the Q1 2026 compared to the fourth quarter 2026 at no. .

Explain Quick Ratio?
How much Cash & cash equivalents PTIX�s has?
What are PTIX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PTIX Quick Ratio	(Jun 30 2026) Q1	(Mar 31 2026) Q4	(Dec 31 2025) Q3	(Sep 30 2025) Q2	(Jun 30 2025) Q1
Y / Y Current Liabilities Change	-88.83 %	-4.23 %	623.78 %	1129.37 %	1323.84 %
Y / Y Cash & cash equivalent Change	-	10308.12 %	20.35 %	157.86 %	343.03 %
Quick Ratio MRQ	-	1.46	0.32	0.28	0.43
PTIX's Total Ranking	#	#	#	#	#
Seq. Current Liabilities Change	3.99 %	-84.88 %	-29.68 %	1.02 %	791.85 %
Seq. Cash & cash equivalent Change	-	-31.79 %	-18.73 %	-33.54 %	28149.66 %

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	#
Healthcare Sector	#
Overall Market	#

Quick Ratio Statistics
High	Average	Low
0	0	0

Financial Statements
Protagenic Therapeutics Inc New's Current Liabilities	$ 1 Millions	Visit PTIX's Balance sheet
Protagenic Therapeutics Inc New's Cash & cash equivalent	$ 0 Millions	Visit PTIX's Balance sheet
Source of PTIX's Sales		Visit PTIX's Sales by Geography

Cumulative Protagenic Therapeutics Inc New's Quick Ratio

PTIX's Quick Ratio for the trailling 12 Months

PTIX Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	50.08 %	679.74 %	853.78 %	731.42 %	306.21 %
Y / Y Cash & cash equivalent TTM Growth	-8 %	174.97 %	44.9 %	2.5 %	-44.74 %
Quick Ratio TTM	0.35	0.39	0.33	0.41	0.56
Total Ranking TTM	# 2964	# 2104	# 1953	# 1768	# 881
Seq. Current Liabilities TTM Growth	-31.41 %	-0.17 %	27.57 %	71.81 %	256.35 %
Seq. Cash & cash equivalent TTM Growth	-38.86 %	16.52 %	4.31 %	23.79 %	82.74 %

Quick ratio ranking by company, industry and sector >> Back to PTIX Financial Strength Comparisons >> Go to Compare PTIX Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in PTIX's Current Liabilities to $1.07 millions, cumulative Quick Ratio to 0.35 below the PTIX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 488 other companies have achieved higher Quick Ratio than Protagenic Therapeutics Inc New. While overall ranking is unchanged compared to the previous 12 months at no. 0.

Explain Quick Ratio?
How much Cash & cash equivalents PTIX�s has?
What are PTIX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 489
Healthcare Sector	# 1003
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
5.29	1.55	0.11
(Dec 31 2016)		(Dec 31 2015)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry

Quick Ratio

Jun 30 2026 MRQ Cash & cash equivalent

Jun 30 2026 MRQ Current Liabilities

Date modified: 2026-08-20T08:17:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.